September 6, 2024
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read more
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read moreCatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
Read moreMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Read moreEnhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
Read moreCerta Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
Read moreBrandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease
Read moreRecruitment completes for second Phase III hypertension trial investigating GMRx2 (George Medicines)
Read moreVAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH
Read moreCUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read moreGlyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
Read moreTech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment
Read moreNasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Read moreGround-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Read moreAravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile
Read moreVaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate
Read moreVaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
Read moreFirst in-human use of OncoRes Medical’s cancer imaging technology successful
Read moreAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Read moreAzura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Read moreGlyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Read moreMedisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension
Read more$16m cash injection to progress first-in-class therapy for inflammation and fibrosis
Read moreAmaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Read moreENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
Read moreGlyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Read morePathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022
Read moreENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
Read morePolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Read moreLife science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator
Read moreGlyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment
Read morePromising new potential treatment for leading cause of Dry Eye Disease a step closer as Azura Ophthalmics announces positive results in Phase 2 Program
Read moreWith health policy top of the political agenda, now’s the time to supercharge Australia’s biotech sector says new MRCF Board member
Read moreVaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Read moreFDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System
Read morePerth tech joint-winner in global finals for international start-up competition
Read moreAravax reveals positive Phase I trial results at world-leading allergy conference
Read moreAustralian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Read moreAustralian biotech company launched with AU$7m investment to develop therapies for treating obesity
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
